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In USA alone therapy-related cancers, either hematological or solid, among cancer survivors account about 18% of all incident cancers, surpassing primary cancers of the breast, lung, and prostate.
1 Therapy-related myeloid neoplasms (t-MNs) include therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML). Patients with t-MDS or t-AML have similar survival rates while patients with complex and unfavorable karyotypes tend to have poorer prognosis regardless of morphologic presentation and myeloblast percentage. 2 Mutations in TP53 and ATM (ataxia telangiectasia mutated) are considered risk factors due to their important roles in the DNA damage response (DDR) pathways. 3, 4 At present there is no active medical intervention to prevent the risk of these therapyinduced cancers. In addition, mouse models that demonstrate a delay of therapy-related malignancies have not yet been described.
Genotoxic therapies generate DNA damage, including potentially deleterious DNA double-strand breaks (DSBs) that may be repaired by non-homologous end joining (NHEJ). 5, 6 NHEJ does not utilize extensive homology for DSB end joining and is active throughout the entire cell cycle. NHEJ consists of the classical (C-NHEJ) and alternative (A-EJ) NHEJ pathways. 6, 7 The C-NHEJ pathway enables direct joins and low microhomology usage (1-3 nucleotides (nt)) at DSB repaired junctions, and A-EJ prefers longer microhomologymediated end joining (≥4 nt) at ligation sites.
Aprataxin and PNKP-like factor (APLF, also referred to as Xip1, C2orf13, and PALF) is a poly(ADP-ribose) or PARbinding protein that interacts with C-NHEJ repair factors, XRCC4-DNA ligase 4 and Ku, to facilitate C-NHEJ in a PAR polymerase 3 (PARP3)-dependent manner. [8] [9] [10] APLF can undergo ATM-and PARP3-dependent phosphorylation at serine-116 following ionizing radiation (IR), which is critical for the recruitment of APLF to the sites of DNA lesion to resolve γH2AX DNA damage signals. 11 Accumulation of APLF to DSBs has been demonstrated to promote the retention of XRCC4/DNA ligase 4 complex in chromatin to facilitate DNA ligation during C-NHEJ. 10 Furthermore, a phospho-ablative mutant of APLF (APLF S116A ), which disabled IR-induced phosphoryation at serine-116 of APLF, exhibited higher persistent γH2AX DNA damage signal and lower cellular survival in colony formation assays after IR exposure reminiscent of cells with APLF depletion. 11 These data suggest that APLF works downstream of ATM and PARP3 to modulate C-NHEJ after IR treatment.
Ionizing radiation and reactive oxygen species (ROS) generate DSBs with chemically modified ends, which require DNA end processing before end joining. Nucleases such as Artemis and APLF, and end processing enzymes such as PNKP (polynuceotide kinase/phosphatase), may participate in processing IR-or ROS-damaged DNA ends for DNA damage repair. 6 Here we report that a moderate reduction of C-NHEJ activity by the depletion of APLF impedes radiation-induced oncogenic translocation in normal tissues and malignancyassociated mortality.
Results

Aplf
-/-mice are moderately impaired in C-NHEJ activity without a switch to A-EJ. To assess the in vivo contribution of the NHEJ pathway in therapy-induced malignancies, we used a mouse model with reduced C-NHEJ activity by creating a frameshift disruption of the entire coding region of APLF (Supplementary Figure S1) , in contrast to an earlier published APLF gene-trapped mouse model, 10 whereby only the C-terminal half of the APLF was deleted leaving the binding sites for XRCC1/4 and Ku80 intact. 9, 12 Although the C-NHEJ pathway functions in V(D)J recombination for B-and T-cell development 13 and in class switch recombination (CSR) 14 of immunoglobulin heavy chain (IgH), Aplf Figures  S2D and E) , suggesting that APLF is either not functional or functionally redundant in the immune system. In contrast, mouse embryonic fibroblasts (MEFs) from Aplf -/-mice showed reduced NHEJ activity ( Figure 1a ) consistent with previous studies in human cell lines with depletion of APLF expression. 9 On the other hand, Aplf -/-mice displayed a reduction, albeit not elimination, 7 of direct joins in the CSR switch junctions (Figure 1b and Supplementary Figure S3 ). 10 Importantly, there was a concurrent increase of very short microhomology of one nucleotide at switch junctions, suggesting a change in the repairing pattern within the C-NHEJ pathway. Nevertheless, there was no significant increased use of longer microhomology (≥4 nt) and, therefore, we did not observe a switch from the C-NHEJ to the A-EJ pathway in Aplf Figures S2D and E) , these data strongly suggest that there is a moderate attenuation of C-NHEJ activity in these Aplf -/-mice but the C-NHEJ pathway is functional and still predominating without switching to the A-EJ pathway. Loss of APLF may be compensated partially by other C-NHEJ factors to support C-NHEJ activity and to prevent a switch to the A-EJ pathway. As a major loss of C-NHEJ function, such as the deficiency of DNA-PKcs, Ku70, Ku80, XRCC4, DNA ligase 4, or Artemis, can lead to a number of intrinsic health issues such as growth defects, immunodeficiency, or inherent chromosomal instabilities, 13, 15 the Aplf -/-mouse, with moderate impairment of the C-NHEJ pathway and specific sensitivities to genotoxic treatments, becomes a good model to address therapy-induced malignant evolution.
Aplf -/-mice have higher p53-mediated cell death upon IR, but less dividing cells with DNA damage and lower frequency of translocation. Following IR, isolated thymocytes from Aplf -/-mice in culture medium exhibited increased Figure 1 Aplf -/-mice have lower extrachromosomal NHEJ and less DNA direct end joining at the switch junctions in B cells, but no switch to the alternative NHEJ (A-EJ) pathway. (a) Extrachromosomal NHEJ assays of I-SceI digested incompatible DNA ends. Data are means ± standard deviation (S.D.) (n = 6) relative to wild-type controls. ***Po0.001; unpaired two-tailed Student's t-test. (b) Microhomology at Sμ-Sγ1 junctions. The number of clones (n) sequenced was compiled from five independent experiments. nt, number of nucleotides at switch junctions. Po0.05 is considered statistically significant; two-tailed Fisher's exact test. (c) Frequencies of C-NHEJ (0-3 nt) and A-EJ (≥4 nt) at the Sμ-Sγ1 switch junctions. The P-values were evaluated by two-tailed Fisher's exact test against wild-type controls. NS, not significant cell death after exposure to 2 and 3 Gray (Gy) (Figure 2a) . Thymus of Aplf -/-mice exposed to whole-body irradiation at 6 Gy also showed elevated p53-dependent apoptosis (4.1% in WT, 21.2% in Aplf -/-, 0% in Aplf -/-p53 -/-) ( Figure 2b ). Following IR treatment, γH2AX can be induced by ATMmediated DDR 16, 17 and by DNA-PK during apoptotic DNA fragmentation. 18 In line with this, isolated bone marrow cells of Aplf -/-mice in culture medium had higher γH2AX-positive cells hours following exposure to 2 Gy IR (Figure 2c and Supplementary Figures S4) , IR induced elevated level of stabilized p53 (Supplementary Figure S11) (Figure 3a and Supplementary Figure S5 ). We found more bone marrow metaphases without chromosome or chromatid breaks in Aplf -/-than wild type 8 h post IR (11.3% in WT versus 25.5% in Aplf -/-) (Figures 3b  and c) . However, this phenotype was reverted by the simultaneous deletion of p53 (9.5% in Aplf -/-
p53
-/-) demonstrating that p53-mediated cell death could efficiently eliminate damaged cells from transmitting DNA damage to the daughter cells (Figure 3b) . By 24 h following IR, the proportion of undamaged cycling cells was comparable in all four genotypes (wild type, Aplf
, p53 -/-) likely due to either DNA repair or clearance by cell death (Figure 3b ). Since DNA damage can be repaired faithfully or unfaithfully, we therefore evaluated the extent of chromosomal aberrations after the induction of a large amount of DSBs by IR. Early evasion of damaged cells in Aplf -/-mice by the p53-mediated cell death pathway led to a lower translocation incidence than in wild type (20 
IR-treated Aplf
-/-mice have less clonal chromosomal translocations in bone marrow 5 months after IR. We exposed animals to a small dose of whole-body irradiation at 50 milliGray (mGy) followed by a higher dose of 6 Gy after a 48-h interval to reduce radiation toxicity to normal tissues ( Figure 5a) . 19, 20 Aplf -/-mice invariably showed overall higher rates of p53-mediated cell death compared with wild-type mice (86.4% live cells in WT, 70.8% live cells in Aplf , normalized by non-irradiated controls; n = 3). Gy, Gray. *Po0.05; unpaired two-tailed Student's t-test. (b) TUNEL staining of thymi from mice 24 h after whole-body 6 Gy IR. Percentage of area that stained TUNEL (apoptosis) positive, as depicted, was quantified by ImageJ software. 37 Scale bars, 500 μM. (c) Quantification of isolated bone marrow cells with ATM-mediated γH2AX (pS139) DNA damage signal at the indicated time after 2 Gy IR (mean ± S.D.; n = 3). C, non-irradiated control. *P o0.05; **Po0.01; ***Po0.001; unpaired two-tailed Student's t-test survival and proliferative advantages. Therefore, we also looked into the long-term effects of IR on the animals. Five months after radiation exposure, wild-type mice had two-to fivefold higher mean chromosomal translocation rates than those of the Aplf -/-mice ( Figure 5c ). Most samples showed complex karyotypes. In particular, irradiated wild-type mice had one or more prominent clonal chromosomal rearrangements ranged from 30 to 70% in frequency, while those in Aplf -/-mice were fewer with a frequency of 25% or lower (Figures 5d-f ).
Reduced C-NHEJ capacity in Aplf -/-mice delays IRinduced dysplasia in hematopoietic cells and malignancyrelated mortality. To examine the impact of reduced NHEJ activity on therapy-related carcinogenesis, we monitored mouse cohorts exposed to 50 mGy followed by 6 Gy after 48 h. (Figure 3d ). Myeloid neoplasms resembling myeloid dysplasia 21 were observed in these moribund or deceased irradiated wild type, Aplf
, and p53 -/-animals. Of note, apart from about 30% of the irradiated Aplf
-/-and p53 -/-mice that died immediately from thymic lymphoma, reminiscent of p53 -/-mice ( Figure 6b and Supplementary Figure S8B ), 22 there was no development of thymic lymphoma identified in the necropsies from the rest of the IR-treated wild type, Aplf
, and p53 -/-mice examined. These affected wild type, Aplf
, and p53 -/-mice had either hypo-or hyper-cellular bone marrow (Figure 6c ). Excessive proliferation of myeloblasts was not observed. In contrast, these animals showed abnormal hematopoiesis in peripheral blood and bone marrow, including hypersegmentation in granulocytes; Howell-Jolly bodies, polychromasia, and poikilocytosis in erythrocytes; binucleated erythroblasts; and dysplastic megakaryocytes with hypolobated nuclei or multiple separate nuclear lobes (Figures 6d-g ). These features are consistent with single-and multi-lineage dysplasia and anemic conditions of human MDS or t-MDS. A case of neutropenia was also noted. IR-treated moribund wild-type mice have oncogenic clonal chromosomal aberrations. We examined an IRtreated moribund wild-type mouse cytogenetically and found complex chromosomal rearrangements of t(9;11), t(Y;16) del (13) , and t(2;16) del (8) (Figure 7a ). The t(9;11) clone, both in the spleen and the bone marrow (Figures 7b-g ), showed a single copy deletion of the Hoxb gene cluster and translocations of both Rara and the oncogene Ets1. Downregulation of either HOXB1 23 or HOXB9 24 has been previously observed in a number of human AML cell lines and patient samples; hence, their functional roles in the proper differentiation of the myeloid lineage have been proposed. Chromosomal rearrangements of the RARA 25 or the ETS1 26 locus have also been reported in patients with myeloid neoplasms. 
Discussion
In this present study, we found that APLF deficiency in mice modestly reduced DNA damage repair and NHEJ activity. APLF-depleted cells, both ex vivo and in vivo, exhibited higher rates of radiation-induced p53-dependent cell death (Figures 2 and 5b ) and fewer chromosomal translocations (Figures 3 and 5c-f) following IR exposure. IR-treated mutant mice showed a delay in malignancy-induced mortality. Simultaneous deficiency of p53 dampened IR-induced apoptosis and have reverted the benefit of impaired DNA repair on mortality in irradiated APLF-deficient mice. Depletion of APLF in non-tumorigenic human cells also markedly reduced the frequency of radiation-induced chromosomal aberrations.
Mice with deficiencies of both C-NHEJ (XRCC4 or DNA ligase 4) and p53 had increased incidence of B-cell lymphomas associated with c-myc/IgH oncogenic translocations. The c-myc/IgH breakpoint junctions of more than 50% of tumors studied were made of short homology (≤3 nt), typical of C-NHEJ. 27 In wild-type mouse B cells, C-NHEJ has been found to promote c-myc/IgH rearrangements with blunt and low microhomolgy (1-3 nt) at breakpoints. 28 Recent reports showed that extensive microhomology-mediated joining (≥4 nt) at rearrangement breakpoints, one of the major features of A-EJ, appears to be less frequent in de novo human translocations found in human cancer samples. 29, 30 An analysis of primary human prostate cancers showed that most chromosomal fusions in these patient cancer tissues involved direct joins at the rearrangement junctions. 31 Other studies in human breast and pancreatic cancers revealed that the most frequent junctions involved 0-3 nt at rearrangement breakpoints. 32, 33 Our findings also showed higher rates of translocation in bone marrow cells of wild-type mice after exposure to IR, which was reduced by impairing C-NHEJ after knocking out Aplf. Depletion of APLF in the non-tumorigenic human breast cell line MCF10A also led to significant reduction of IR-induced chromosomal translocation. While genomic abnormalities in cancers are complex and diverse, the role of non-homologous end joining in somatic rearrangements is appreciated. 29, 30, 32 The contribution of A-EJ to somatic translocations is still of particular interest since studies have showed an apparent interplay between C-NHEJ and A-EJ in modulating genome stability and translocations featuring longer microhomologies especially in cells lacking Ku or other core C-NHEJ factors. 27, [34] [35] [36] [37] Deletion of genetic sequences is found frequently in cells from human patients. 29, 30, 33 We also detected both translocations and deletion of gene clusters after chromosomal rearrangement in irradiated wild-type mice and human non-tumorigenic MCF10A cells. Loss of part or all of chromosomes 5 (5q-/-5) and/or 7 (7q-/-7), complex cytogenetics, and a poor response to chemotherapy are characteristic findings in t-MN patients. 38 Mutations found in t-MN patients include those observed in patients with de novo MDS and AML: FLT3, cKIT, PTPN11, NRAS, RAS, BRAF, c-FMS, JAK2, CEBPA, TP53, and AML1 genes. 39 Previous studies suggest that about 30% of t-MN patient carry loss-of-function mutations in TP53.
4,38 A recent study indicates that the high frequency of TP53 mutations in t-MN patients may not be directly induced by genotoxic treatments. But, rather, when there are age-related loss-of-function mutations of TP53 in rare hematopoietic stem/progenitor cells, these cells may become resistant to chemo-and radiotherapies and hence can preferentially expand even after treatment. 4 Another rational explanation, as demonstrated by the present study, is that when the p53-mediated cell death pathway is impaired due to mutations in TP53, instead of clearing away severely damaged cells, more cells carrying DNA DSBs will survive and are repaired by the C-NHEJ pathway faithfully and unfaithfully. Therefore, mutations in TP53 are frequent in t-MN patients and (9)t(9;11)] (white arrow), and derivative chromosome 11 [der(11)t(9,11)] (white arrowhead) are associated with the higher risk of chromosomal abnormality formation and malignant transformation after genotoxic therapies.
Li et al. have generated mice bearing lysine to arginine mutations at the acetylation sites in p53. These mutations did not affect the metabolic regulation and antioxidant function of p53 but seemed sufficient for inhibiting early-onset spontaneous thymic lymphoma usually found in p53 null mice. 22, 40 Cellular DNA damages trigger a spectrum of signaling which leads to the stabilization of p53, ATM/ATR-associated direct phosphorylation of Ser18 of p53 in mice (Ser15 in human p53) and ATM/ATR-associated indirect phosphorylation of Ser23 of p53 in mice (Ser20 in human p53) via chk2 protein kinase. 16, 17 Mice that harbor alanine substitutions of these two key DNA damage-targeted phosphorylation sites of Ser18 and Ser23 in p53 are resistant to IR-induced p53-dependent apoptosis. These alanine substituted p53 mutant mice developed an array of malignancies, thereby reinforcing a link between p53-dependent DDRs and tumor suppression. 41 Another study also showed that mice with a single alanine substitution at Ser18 of p53, instead of developing early-onset spontaneous tumors like those found in p53 null mice, were succumbed to late-onset lymphomas, demonstrating that DDR function of p53 is important to tumor suppression in vivo. 42 The current study demonstrates that the C-NHEJ pathway plays a role in producing genomic abnormalities in particular following the induction of a large number of DSBs from genotoxic treatments. We conclude that the more error-prone NHEJ DNA damage repair, even when the classical NHEJ pathway predominates, can promote genomic instability in normal tissues after genotoxic therapies. Carcinogenesis can be driven by complex chromosomal rearrangements, deletions or mutations. Manipulation of the efficiency in DNA damage repair may have the potential to intervene in the development of these diseases.
Genotoxic therapy-induced cell death is the common rationale behind most cancer therapies. This approach needs to be balanced against the risk of therapy-induced acute and late toxic side effects in normal tissues, such as anemia, fibrosis, and second cancers, which may limit the efficacy of therapy that can be administered to patients. 43 This is an important area of investigation that warrants further exploration in future studies. Central to this notion is whether sensitizing TP53 during cancer therapies augments therapyrelated toxicity. The present study demonstrates that one of the most serious and deadly therapy-induced toxic side effects, second cancers, could potentially be reduced. Indeed, the balance of excessive cell death and evasion of damaged cells need to be carefully controlled to maximize the benefits of TP53 as the guardian of genome. Gene-targeted deletion of murine Aplf locus. The targeting construct was designed to replace exons 2-3 of Aplf by PGK promoter-driven neomycin resistance gene, which would create frameshift mutation starting within the Forkhead associated domain. Targeting vector was linearized by NotI digestion and electroporated into E14K embryonic stem (ES) cells (129/Ola). G418-resistant ES cell clones were then screened for homologous recombination by nested PCR. Candidate ES cells clones were further confirmed by Southern blot with PCR-generated probes (1 and 2) as described in Supplementary Figure S1A , using the standard method. Four correctly targeted clones were confirmed and three were injected into C57BL/6J blastocysts. Two independent mouse lines were successfully established using standard procedures.
Southern blot analysis. Genomic DNA was extracted from the indicated ES cell clones. BamHI-digested DNA was resolved by electrophoresis, transferred onto nitrocellulose membrane, and hybridized by 32 P radioactive probes using the standard method as described in the legend of Supplementary Figure S1A . Probed membranes were exposed to storage phosphor screen (Perkin Elmer, Waltham, MA, USA). Images were captured by the Typhoon Trio Imager (GE Healthcare, Chicago, IL, USA).
Primers. Aplf
-/-mice were genotyped using following primers: (2637U) 5′-CTTA CTGGGCTTGACTTTAGAC-3′; (3570) 5′-GGCTTGATTCGAAGCTGACTAT-3′; and (2995L) 5′-CATCGCCTTCTATCGCCTTCTT-3′ as primers a, b, c described in Extended Data Figure S1a . The following primers were used for the semiquantitative PCR: Aplf, forward 5′-GAATCAAGCCAATCCATAGGAATC-3′ and reverse 5′-CATCTGACTGTTTCTCAGAGTAC-3′. The following primers were used for qRT-PCR: Puma forward 5′-CTGGAGGGTCATGTACAATCTCTT-3′ and reverse 5′-CACCTAGTTGGGCTCCATTTCT-3′; mdm2, forward 5′-GGATCTTGACGATGGC GTAAG-3′ and reverse 5′-AGGCTGTAATCTTCCGAGTCC-3′; APLF1, forward 5′-CCGCTGCTGGGAATAACAGA-3′ and reverse 5′-GCTTCAATGGTAAGAGCTG ACT-3′; APLF2, forward 5′-CAGCTCTTACCATTGAAGCCA-3′ and reverse 5′-CCA GTTGTGAGGCACCAGTAG-3′ primers.
Animal studies. Procedures for maintaining mice and all experiments described were approved by the Ontario Cancer Institute Animal Facility and were performed in compliance with the regulations of the Animal Ethics and Animal Care Committees at the Princess Margaret Cancer Centre. Unless indicated in the figure legends, Aplf -/-mice used in the analyses have been backcrossed with C57BL/6J mice for six generations. p53 +/-mouse was purchased from Taconic. Atm-knockout mouse 44 , respectively. For mouse cohort studies, mice of 2 months old were exposed firstly to 50 mGy (at 28.84 cGy/min) of irradiation, followed by 6 Gy (at 108.25 cGy/ min) treatment 48 h later by X-RAD 320, an X-ray irradiator (Precision X-Ray, North Branford, CT, USA). Mice were killed and necropsied at end points of either morbidity or mortality. Mouse tissues were extracted and processed as described in the Histology section.
Lymphocyte development, class switch recombination, and switch junction analyses. For analysis of lymphocyte development, single-cell suspensions were prepared from the bone marrow, thymus, and spleen from mice of 6-8 weeks old. 1 × 10 6 cells were stained by fluorescence-conjugated antibodies as indicated. Data were obtained by FACSCalibur flow cytometer (BD Biosciences) and interpreted by FLOWJO software (Tree Star, Ashland, OR, USA). For class switch recombination assays, splenic CD43 -B cells were isolated by immunomagnetic depletion using biotinylated anti-CD43 and streptavidin particles. Cells at 5 × 10 5 /ml were stimulated for 4 days by 10 ng/ml of IL-4 plus 20 μg/ml of LPS in RPMI-1640-rich medium (containing 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 4.5 g/l glucose, and 1.5 g/l sodium bicarbonate) supplemented with 10% (vol/vol) fetal bovine serum (FBS) and 50 μM β-mercaptoethanol. Data were obtained by flow cytometry as described above. For Sμ-Sγ1 switch junction analysis, splenic CD43
-B cells were isolated and stimulated by IL-4 and LPS for 4 days as mentioned above. The Sμ-Sγ1 junction regions were amplified by PCR from extracted genomic DNA and cloned into PCR2.1 vector for sequencing using Topo-TA cloning kit (Invitrogen) as described previously. 45 Sequence data were analyzed by pairwise sequence alignment tool (EMBOSS, EMBL-EBI) using GenBank files MUSIGCD07 (for Sμ) and MUSIGHANB (for Sγ1) for IgM and IgG1 switch regions, respectively.
Cell death assay. Isolated thymocytes were maintained ex vivo in RPMI-1640-rich medium supplemented with 10% FBS and 50 μM β-mercaptoethanol. Cells were either treated or non-treated by γ-irradiation using Cs137 based Gammacell 40 Exactor (Nordion International Inc., Ottawa, ON, Canada) at 0.78 Gy/min to induce DNA damage with dosage as indicated. Twenty-four hours later, cells were co-stained by Annexin V-FITC and PI or 7-AAD, and analyzed by flow cytometry. Proportion of live cells was determined by estimating percentage of cells negative to both Annexin V and PI (or 7-AAD) staining. The percentage of live cells was normalized by non-irradiated controls. For whole-body γ-irradiation, 4-to 6-week-old mice were γ-irradiated as described in the text and figure legends. The thymus was extracted from mice 24 h after IR treatment, stained, and analyzed as mentioned above. MCF10 cells were transfected with control and APLF siRNA. After 48 h, the cells were treated by 2 Gy IR and apoptotic cells were quantified with Annexin V and PI staining.
Histology. Thymus tissue was extracted from mice after γ-irradiation as described in the figure legends, fixed in neutral buffered formalin (Sigma), paraffinembedded, sectioned, and stained by TUNEL. Buffered formalin fixed femurs were paraffin-embedded after decalcified with 10% EDTA, pH 7.4. Paraffin sections on slides were heated by microwave in 50 mM citrate buffer for antigen retrieval. Sections were stained by antimyeloperoxidase (ab9535; Abcam, Cambridge, MA, USA) using the standard methods. DNA was counterstained by hematoxylin. Hematoxylin and eosin (H&E) and Giemsa stainings of paraffin-embedded sections were prepared by standard procedures. Peripheral blood was collected by the cardiac puncture method and blood smears were stained by Wright's stain (EMD Millipore, Billerica, MA, USA) according to the supplier's protocol.
Extrachromosomal NHEJ assay. Primary MEFs of wild type and Aplf -/-mice were generated from mouse embryos at E13.5 and immortalized by SV40 T antigen using the standard method. Immortalized MEFs were maintained in DMEM high-glucose (4.5 g/l) medium supplemented with 10% FBS and 0.8 μg/ml of puromycin. I-SceI-linearized pEGFP-Pem1-Ad2 46 was co-transfected with pDsRedMono-N1 (Clontech, Mountain View, CA, USA), as the transfection control, into immortalized MEFs by Amaxa Nucleofector MEF 1 reagent (Lonza, Basel, Switzerland) following the manufacturer's manual. Cells were analyzed 48 h post transfection by flow cytometry using the FACSCalibur and FLOWJO software to estimate re-circularized pEGFP-Pem1-Ad2. Rejoining efficiency was determined by the ratio of GFP + /RFP + cells, relative to that of wild-type controls.
γH2AX-positive cells quantification. Total bone marrow cells were extracted from femurs and tibias of mice using phosphate-buffered saline (PBS) supplemented with 1% (vol/vol) FBS and 1 mM EDTA. After lysing red blood cells, 1 × 10 6 /ml of nucleated cells were cultured in RPMI-1640-rich medium supplemented with 10% FBS and 50 μM β-mercaptoethanol, recombinant murine Flt3-ligand (20 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml), SCF (20 ng/ml), TPO (50 ng/ml), and recombinant human TSLP (10 ng/ml) for 16 h. After exposed to 2 Gy IR, bone marrow cells were harvested at indicated time points, fixed in 2% paraformaldehyde (Sigma), and permeabilized by 90% methanol. 47 Fixed cells were then stained by anti-γH2AX (pS139) conjugated with Alexa Fluor 647 (BD Biosciences) at 4°C for 1 h, followed by PI (30 μg/ml) in the presence of 100 μg/ml RNase A (Thermo Scientific, Waltham, MA, USA) for 60 min at room temperature in dark. At least 10 000 cells of each sample were analyzed as described 47 by FACSCanto (BD Biosciences) and interpreted by FLOWJO software.
Cell cycle analysis. Red blood cell-depleted spleen cells were cultured at 1 × 10 6 / ml in RPMI-1640-rich medium supplemented with 10% FBS and 50 μM β-mercaptoethanol, IL-4 (10 ng/ml), and LPS (20 μg/ml) for 48 h. Cells were then irradiated (2 Gy, X-RAD 320), harvested at the indicated time as described in the text and figures, and fixed in ice-cold 70% ethanol. Fixed cells were stained by PI (27 μg/ml) in the presence of 100 μg/ml RNase A for 60 min at room temperature in dark. DNA content was measured by flow cytometry and analyzed by FLOWJO. To assess the G2/M checkpoint by flow cytometry, fixed cells were permeabilized in 0.1% Triton X-100/PBS buffer for 15 min at room temperature before staining by Alexa Fluor 488-conjugated phospho-histone-H3 (pSer10) antibody (New England BioLabs, Ipswich, MA, USA).
Ex vivo bone marrow metaphase preparation. Total bone marrow cells were extracted from femurs and tibias of mice using PBS supplemented with 1% FBS and 1 mM EDTA. After lysing red blood cells, nucleated cells were cultured in RPMI-1640-rich medium supplemented with 10% FBS and 50 μM β-mercaptoethanol, recombinant murine Flt3-ligand (20 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml), SCF (20 ng/ml), TPO (50 ng/ml), and recombinant human TSLP (10 ng/ ml). After 24 h, bone marrow cells were exposed to 2 Gy IR (X-RAD 320). One hour before harvesting cells, 150 ng/ml of colcemid (Roche, Basel, Switzerland) was added to the culture. Cells were then harvested, treated in 75 mM potassium chloride (KCl) at 37°C for 20 min, and fixed with ice-cold methanol/acetic acid (3:1) fixative. Fixed cells were then dropped on slides to generate metaphase spreads. Slides were allowed to dry overnight and then mounted with Vectorshield containing DAPI (Vector Laboratories, Burlingame, CA, USA) for analysis. Images were taken with AxioImager Z1 (Zeiss, Oberkochen, Germany) equipped with Metamorph software (Molecular Devices, Sunnyvale, CA, USA).
Direct bone marrow metaphase preparation. Total bone marrow cells from whole-body irradiated mice were extracted by RPMI-1640-rich medium supplemented with 10% FBS, 50 μM β-mercaptoethanol, and 10 U heparin/ml (Sigma). Cells were treated in 75 mM KCl containing 40 ng/ml of colcemid at 37°C for 20 min, fixed with ice-cold methanol/acetic acid, and dropped on slides. Air-dried slides were processed for two-and three-color FISH or three-color whole chromosome paint as described below.
Multicolor FISH (M-FISH).
Red blood cell-depleted spleen cells were cultured in RPMI-1640-rich medium supplemented with 10% FBS and 50 μM β-mercaptoethanol, recombinant murine Flt3-ligand (20 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml), SCF (20 ng/ml), TPO (50 ng/ml), IL-4 (10 ng/ml), recombinant human TSLP (10 ng/ml), and LPS (20 μg/ml) for 48 h. One hour before harvesting cells, 150 ng/ml of colcemid (Roche) was added to the culture. Cells were then harvested, treated in 75 mM potassium chloride (KCl) at 37°C for 20 min, and fixed with icecold methanol/acetic acid (3:1) fixative. Fixed cells were then dropped on slides. Slides containing metaphases were stained with mouse m-FISH kit (21XMouse) to identify chromosome aberrations according to the supplier's protocol (MetaSystems, Altussheim, Germany). Metaphase spreads were captured at × 630 magnification on an Imager M1 Zeiss microscope (Carl Zeiss Canada Limited, Toronto, ON, Canada) equipped with the appropriate filters. The JAI CV-M4+CL progressive scan monochrome camera (JAI Inc., San Jose, CA, USA) and the MetaSystems Isis FISH Imaging software programs v5.3 (MetaSystems) were used for analysis. Gene-specific probes were applied, as described below, to confirm specific translocations as M-FISH has some limitations in delineations of chromosomal rearrangements.
Mouse BAC clones probe preparation. Mouse BAC clones encompass the locus containing Hoxb (RP23-205E11 and RP23-9G13), Ets1 (RP23-403F11 and RP23-101N3), Sept4 (RP23-333D13), or Rara (RP23-333D2 and RP23-364P11). BAC clones were verified by PCR using primers against regions of each gene. Probes were prepared by nick translation kit using green dUTP, orange dUTP, or Aqua dUTP according to the manufacturer's protocol (Abbott Molecular, Des Plaines, IL, USA). At least 100 ng of each probe was used in hybridization.
Two-and three-color FISH. Metaphases on slides were treated by 100 μg/ ml RNase A (Thermo Scientific) in 2 × SSC for 1 h at 37°C, washed 2 × 5 min in 2 × SSC. Fixed in 4% formaldehyde for 10 min. Washed 2 × 5 min in 2 × SSC and dehydrated in 70, 90, and 100% ethanol. The slides were then treated with 70% formamide in 2 × SSC at 75°C for 5 min. Rinsed briefly in cold 2 × SSC, once in 70% ethanol (5 min, -20°C), and dehydrated with 90 and 100% ethanol at room temperature. Fluorescent probes were denatured in 50% Formamide, 10% (w/v) dextran sulfate, 1 × SSC and 20 × (w/w) mouse Cot1 DNA (Invitrogen) at 75°C for 10 min, applied to the slides, and incubated overnight in a humidified chamber at 37°C. Slides were then washed once in 0.4 × SSC/0.3% Tween 20 at 74°C for 5 min and once in 4 × SSC/0.1% Tween 20 at room temperature for 2 min. Dehydrated, air dried, and mounted with Vectorshield containing DAPI. Images were obtained using AxioImager Z1 equipped with Metamorph software.
Whole chromosome paint. Metaphases were stained by 3-color whole mouse chromosome paint (Applied Spectral Imaging, Carlsbad, CA, USA) in red (chromosome 2 or 9), green (chromosome 6 or 11), and aqua (chromosome 12 or 15) or by three-color whole human chromosome paint (Applied Spectral Imaging) in red (chromosome 8 or 11), green (chromosome 5 or 21), and aqua (chromosome 7 or 15) according to the manufacturer's protocol. Slides were counterstained with Vectorshield containing DAPI. Images were obtained using AxioImager Z1 equipped with Metamorph software.
MCF10A cell culture. MCF10a cells were maintained in DMEM/F12 medium supplemented by 2 mM L-glutamine, 5% horse serum (Life Technologies), 20 ng/ml epidermal growth factor (Peprotech), 0.5 μg/ml hydrocortisone (Sigma), 0.1 μg/ml cholera toxin (Sigma), 10 μg/ml insulin (Sigma), and 50 U/ml of penicillinstreptomycin.
siRNA knockdown of APLF. All siRNA pools were obtained from Dharmacon. For every experiment, 25 nM of four siRNA sequences were used to transfect cells by Dharmafect 1 (Dharmacon, Lafayette, CO, USA) according to the manufacturer's protocol. Cells were treated by 2 Gy IR or harvested for western blot 48 h after.
siRNA sequences against: human APLF, GCACAAGAUAGAAUAUAGA, CUUCAUAUUACGUGACUUU, AGCAAUCAGUGGAGGUAAU, UGAUUAUGGAGG UGUACAA, and non-targeting control, UGGUUUACAUGUCGACUAA, UGGUUUAC AUGUUGUGUGA, UGGUUUACAUGUUUUCUGA, UGGUUUACAUGUUUUCCUA.
Statistical analysis. Differences between groups were assayed using an unpaired two-tailed Student's t-test after evaluation of variance. In cases where the assumption of the t-test was not valid, the non-parametric two-tailed Mann-Whitney test was used. Multiple groups were analyzed by one-way ANOVA with Tukey's post hoc test. A two-tailed Fisher's exact test was used to analyze the contingency table of microhomology length at switch junctions. Survival differences were analyzed by log-rank test. Po0.05 was considered statistically significant.
